3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
28
Neoplasm Metastasis
4
Gastrointestinal Stromal Tumors
4
Colonic Neoplasms
4
Carcinoma, Hepatocellular
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Rectal Neoplasms
2
Gallbladder Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Sarcoma
1
Rhabdomyosarcoma
1
Renal Insufficiency
1
Physician Education
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Noonan Syndrome 6
1
Metastatic Pancreatic Adenocarcinoma
1
Melanoma
1
Liver Neoplasms
1
Interventions
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Physician Education
×
regorafenib
×
Clear all
NCT02287025
2017-10-19
SMART
Bayer
Phase 4
Terminated
23 enrolled
6 charts